A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapse/Refractory to Janus Kinase (JAK) Inhibitor
Description: 

The primary objectives of this study are to evaluate spleen response rate and symptom response rate of 2 dose regimens of imetelstat (9.4 mg/kg and 4.7 mg/kg imetelstat given intravenous [IV] every 3 weeks)
in subjects with intermediate-2 or high-risk MF who are relapsed after or refractory to JAK inhibitor treatment.

Study Number: 

PH 269915

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02426086

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.